🎉 M&A multiples are live!
Check it out!

Voyager Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Voyager Therapeutics and similar public comparables like Pharming, Galapagos, and Benevolent AI.

Voyager Therapeutics Overview

About Voyager Therapeutics

Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.


Founded

2013

HQ

United States of America
Employees

172

Financials

LTM Revenue $76.0M

LTM EBITDA -$89.5M

EV

-$46.8M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Voyager Therapeutics Financials

Voyager Therapeutics has a last 12-month revenue of $76.0M and a last 12-month EBITDA of -$89.5M.

In the most recent fiscal year, Voyager Therapeutics achieved revenue of $80.0M and an EBITDA of -$78.6M.

Voyager Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Voyager Therapeutics valuation multiples based on analyst estimates

Voyager Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $250M $80.0M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA $126M -$78.6M XXX XXX XXX
EBITDA Margin 51% -98% XXX XXX XXX
Net Profit -$46.4M $132M XXX XXX XXX
Net Margin -19% 165% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Voyager Therapeutics Stock Performance

As of April 15, 2025, Voyager Therapeutics's stock price is $3.

Voyager Therapeutics has current market cap of $176M, and EV of -$46.8M.

See Voyager Therapeutics trading valuation data

Voyager Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$46.8M $176M XXX XXX XXX XXX $-1.29

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Voyager Therapeutics Valuation Multiples

As of April 15, 2025, Voyager Therapeutics has market cap of $176M and EV of -$46.8M.

Voyager Therapeutics's trades at -0.6x LTM EV/Revenue multiple, and 0.5x LTM EBITDA.

Analysts estimate Voyager Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Voyager Therapeutics and 10K+ public comps

Voyager Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$46.8M XXX XXX XXX
EV/Revenue -0.6x XXX XXX XXX
EV/EBITDA 0.6x XXX XXX XXX
P/E -2.7x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF 2.5x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Voyager Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Voyager Therapeutics Valuation Multiples

Voyager Therapeutics's NTM/LTM revenue growth is -13%

Voyager Therapeutics's revenue per employee for the last fiscal year averaged $0.5M, while opex per employee averaged $0.9M for the same period.

Over next 12 months, Voyager Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Voyager Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Voyager Therapeutics and other 10K+ public comps

Voyager Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -68% XXX XXX XXX XXX
EBITDA Margin -98% XXX XXX XXX XXX
EBITDA Growth -162% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -111% XXX XXX XXX XXX
Revenue per Employee $0.5M XXX XXX XXX XXX
Opex per Employee $0.9M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 45% XXX XXX XXX XXX
R&D Expenses to Revenue 159% XXX XXX XXX XXX
Opex to Revenue 204% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Voyager Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics and Genomics & Personalized Medicine comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Voyager Therapeutics M&A and Investment Activity

Voyager Therapeutics acquired  XXX companies to date.

Last acquisition by Voyager Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Voyager Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Voyager Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Voyager Therapeutics

When was Voyager Therapeutics founded? Voyager Therapeutics was founded in 2013.
Where is Voyager Therapeutics headquartered? Voyager Therapeutics is headquartered in United States of America.
How many employees does Voyager Therapeutics have? As of today, Voyager Therapeutics has 172 employees.
Who is the CEO of Voyager Therapeutics? Voyager Therapeutics's CEO is Dr. Alfred W. Sandrock, Jr,M.D.,PhD.
Is Voyager Therapeutics publicy listed? Yes, Voyager Therapeutics is a public company listed on NAS.
What is the stock symbol of Voyager Therapeutics? Voyager Therapeutics trades under VYGR ticker.
When did Voyager Therapeutics go public? Voyager Therapeutics went public in 2015.
Who are competitors of Voyager Therapeutics? Similar companies to Voyager Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Voyager Therapeutics? Voyager Therapeutics's current market cap is $176M
What is the current revenue of Voyager Therapeutics? Voyager Therapeutics's last 12-month revenue is $76.0M.
What is the current EBITDA of Voyager Therapeutics? Voyager Therapeutics's last 12-month EBITDA is -$89.5M.
What is the current EV/Revenue multiple of Voyager Therapeutics? Current revenue multiple of Voyager Therapeutics is -0.6x.
What is the current EV/EBITDA multiple of Voyager Therapeutics? Current EBITDA multiple of Voyager Therapeutics is 0.5x.
What is the current revenue growth of Voyager Therapeutics? Voyager Therapeutics revenue growth between 2023 and 2024 was -68%.
Is Voyager Therapeutics profitable? Yes, Voyager Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.